首页> 外国专利> METHOD FOR DETERMINING RISK OF OCCASIONAL CEREBRAL STROKE IN PATIENTS UNDERWENT CEREBROVASCULAR ACCIDENT

METHOD FOR DETERMINING RISK OF OCCASIONAL CEREBRAL STROKE IN PATIENTS UNDERWENT CEREBROVASCULAR ACCIDENT

机译:确定脑血管意外患者偶然性脑卒中风险的方法

摘要

FIELD: medicine.;SUBSTANCE: invention relates to medicine, namely cardiology and neurology, and can be used to predict the risk of developing a repeated cerebral stroke (CS) in patients underwent a small ischemic stroke, ischemic CS, small hemorrhagic stroke, hemorrhagic CS. Not earlier than 60 days after the CS, in the early recovery period, after the selection of drug therapy in the outpatient monitoring phase of the patient, perform an anamnesis on the presence of concomitant diseases, an additional clinical diagnostic examination – ECG and daily Holter monitoring of the ECG, daily monitoring of blood pressure (BPM) or self-monitoring of blood pressure (BPSM), a biochemical blood test. Identify the presence/absence of arterial hypertension (AH), hyperlipidemia, diabetes mellitus (DM), auricular fibrillation and/or fluttering (AFib/AFlut). Perform an evaluation of the outpatient drug therapy with antihypertensive drugs (AHT) in patients with arterial hypertension (AH), lipid lowering drugs (LLT) in all patients underwent CS, oral anticoagulants (OAC) in patients with AFib/AFlut, disaggregants (DA) in all patients who underwent CS, without AFib/AFlut, sugar-lowering drugs – in patients with DM. Determine the effectiveness of antihypertensive therapy (AHT) for the target level of mean arterial pressure (AP) less than 140/90 mm Hg for patients without DM and less than 130/80 mm Hg – for patients with DM. Evaluation of the type of underwent CS is carried out: small ischemic stroke, ischemic CS, small hemorrhagic stroke, hemorrhagic CS. Patient adherence to the prescribed treatment is determined by the Morisky-Green test. Calculate the risk factor for occasional CS as C(OCSR)= (assigned(AHT+LLT+DA+OAC+DM)–(AHT effect.)+GAI)/(necessary (AHT+LLT+DA+OAC+HGT)+K(CS)), where the assigned – the sum of points for performed pharmacotherapeutic activities, necessary – the sum of the points for the activities that the patient needed to take in view of his/her anamnesis/concomitant diseases, AHT – 1 point value for performing antihypertensive therapy (AHT) in patients with elevated blood pressure, 0 point value for absence of prescription AHT, LLD – 1 point value for performing lipid-lowering therapy (LLT), 0 point value for not assigning, DA – 1 point value for the treatment of disaggregants in patients without auricular fibrillation and/or fluttering, for non-conductance 0 points, UAC – 1 point evaluation for oral anticoagulant therapy in patients with auricular fibrillation and/or fluttering, 0 point value for non-performance, HGT – 1 point value for the performing of hypoglycemic therapy (HGT) in patients with type 2 diabetes mellitus (DM), 0 point value for non-performance, AHT effect. – reaching/failure of target BP levels (reaching – 0 points, failure 0.5 points), GAI – the index of the general adherence of the patient to the prescribed treatment according to the Morisky-Green test (0.5 points for 0 or 1 positive response, -0.5 points with more than 2 positive responses), C(CS) is the reduction coefficient of CS (0 points for a small ischemic stroke, 1 point for all other cases of ischemic stroke and for a small hemorrhagic stroke, 2 points for all other cases of hemorrhagic stroke). At C(OCSR) value greater than or equal to 0.8, a low risk of occasional cerebrovascular accident (CVA) is predicted, with the value of C(OCSR) 0.51–0.79, the risk of occasional CVA is considered average, with a value of C(OCSR) of 0.21–0.5, the risk of occasional CVA is considered high and at a value of C(OCSR) less than or equal to 0.2 predict a very high risk of occasional CVA. Repeated evaluation of treatment is carried out once every three months, with a low and average risk of occasional CVA, once every two months, with a high and very high risk of occasional CVA within the first year after CS and once every six months – after 12 months after this event.;EFFECT: method provides an accurate assessment of the risk of developing a occasional CVA of any genesis by identifying a combination of the most important factors related to the prediction of the occasional CVA.;1 cl, 3 ex
机译:发明领域本发明涉及医学,即心脏病学和神经病学,并且可以用于预测患有小缺血性中风,缺血性CS,小出血性中风,出血的患者发生重复性脑中风(CS)的风险。 CS。在CS发生后不早于60天,在患者的门诊监测阶段选择药物治疗后的早期恢复阶段,对伴有疾病的患者进行回忆检查,另外进行临床诊断检查– ECG和每日动态心电图监测心电图,每日监测血压(BPM)或自我监测血压(BPSM),生化验血。识别是否存在动脉高血压(AH),高脂血症,糖尿病(DM),房颤和/或扑动(AFib / AFlut)。对动脉高血压(AH)患者的降压药物(AHT),所有接受CS的患者的降脂药物(LLT)的门诊药物治疗,AFib / AFlut患者的口服抗凝剂(OAC)和分散剂(DA)进行评估)在所有没有AFib / AFlut且没有DM的CS患者中-DM患者。确定抗高血压治疗(AHT)对于无DM患者的平均动脉压(AP)低于140/90 mm Hg和DM患者小于130/80 mm Hg的目标水平的有效性。评估接受CS的类型:小缺血性中风,缺血性CS,小出血性中风,出血性CS。患者对处方治疗的依从性由Morisky-Green测试确定。计算偶然CS的风险因子为C(OCSR)=(分配的(AHT + LLT + DA + OAC + DM)–(AHT效应。)+ GAI)/(必要的(AHT + LLT + DA + OAC + HGT)+ K(CS)),其中分配的–进行药物治疗活动所需的总点数–鉴于患者的病历/伴随疾病需要进行的各项活动的总点数,AHT – 1分高血压患者进行抗高血压治疗(AHT)的值,无处方AHT的为0分,LLD –进行降脂治疗(LLT)的为1分,未指定的为0分,DA-1分对于没有耳部颤动和/或扑动的患者,治疗不慎使用的药物的价值,非传导性为0分,针对耳腔颤动和/或扑动的患者口服抗凝治疗的UAC为1分,对于无功能者为0分, HGT –对患有以下疾病的患者进行降糖治疗(HGT)的1分值2型糖尿病(DM),无功能,AHT效果为0分。 –达到/失败的目标血压水平(达到– 0点,失败0.5点),GAI –根据Morisky-Green测试,患者对处方治疗的总体依从性指数(0或1个阳性反应为0.5点,-0.5分,且有超过2个阳性反应),C(CS)是CS的降低系数(小缺血性卒中为0分,其他缺血性卒中和小出血性卒中为1分,所有其他出血性中风病例)。在C(OCSR)值大于或等于0.8时,预测发生偶然性脑血管意外(CVA)的风险较低,而C(OCSR)值为0.51-0.79,则将偶然CVA的风险视为平均,其值为如果C(OCSR)的C(OCSR)为0.21-0.5,则CVA的偶然风险较高;如果C(OCSR)的值小于或等于0.2,则CVA的偶然风险很高。每三个月进行一次重复的治疗评估,偶尔发生CVA的风险较低且平均,每两个月进行一次,在CS发生后的第一年内以及之后每六个月–以后,偶尔CVA的风险较高和非常高事件发生后12个月;效果:通过识别与预测偶然CVA相关的最重要因素的组合,该方法可准确评估任何起源的偶然CVA的风险。1cl,3 ex

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号